Tue, Sep 16, 2014, 6:05 AM EDT - U.S. Markets open in 3 hrs 25 mins

Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

weightbayou 165 posts  |  Last Activity: Sep 3, 2014 5:45 PM Member since: Jul 5, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • weightbayou by weightbayou Jul 26, 2014 8:39 PM Flag

    Not yet recruiting A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Conditions: For Donors:; Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling; For Recipients:; Acute Myelogenous Leukemia (AML); Acute Lymphoblastic Leukemia (ALL); Myelodysplastic Syndrome (MDS); Chronic Myelogenous Leukemia (CML); Non-Hodgkins Lymphoma (NHL); Hodgkins Disease (HD); Chronic Lymphocytic Leukemia (CLL)
    Interventions: Drug: CDX-301; Drug: CDX-301 and plerixafor

    Sentiment: Strong Buy

  • Reply to

    Short Screwing Coming

    by j20tower Jul 2, 2014 10:10 AM
    weightbayou weightbayou Jul 2, 2014 3:38 PM Flag

    The remaing months of this yr will be great, imo. Let the new trials begin!

    Sentiment: Strong Buy

  • The BMY news today should help cldx. Look for $18 on Wed.

    “The outcome of CheckMate -066 is an important milestone in the field of immuno-oncology as it represents the first well-controlled, randomized Phase 3 trial of an investigational PD-1 checkpoint inhibitor to demonstrate an overall survival benefit,” said Michael Giordano, MD, Head of Oncology Development. “Bristol-Myers Squibb is committed to continuing to lead advances in immuno-oncology and to executing our strategy to provide patients with the best opportunity to achieve the potential for long term survival.” CheckMate -066 investigators have been informed of the decision to stop the blinded comparative portion of the trial.

  • Last September cldx was over $38. They did not have the BMY and ONTY collaborations then. Furthermore, I bet more collaborations are coming folks.

    Sentiment: Strong Buy

  • weightbayou weightbayou Jun 23, 2014 7:52 PM Flag

    Full enrollment can't be far off. CLDX should regain its footing this week.

    Sentiment: Strong Buy

  • Remember, it was last summer when the huge run up started. Too many irons in the fire.

    Sentiment: Strong Buy

  • Could be because there will be numerous catalysts for the 3rd and 4th qtrs.

    Sentiment: Strong Buy

  • In the 4th quarter there will be more new trials starting than ever before, plus updated cdx-011 data, and other exciting things I am sure.

    Sentiment: Strong Buy

  • Many trials will start later this year.

    Sentiment: Strong Buy

  • If Celldex gets a $1 billion partnership and if data for cdx-011 and cdx-110 beats expectations.

    Sentiment: Strong Buy

  • Reply to

    Bristol-Myers End Up Acquiring Celldex?

    by dinepat203 Jun 23, 2014 2:49 PM
    weightbayou weightbayou Jun 23, 2014 6:15 PM Flag

    Let's hope there there will be a bidding war between BMY, NVS, MRK, and PFE for CLDX.

    Sentiment: Strong Buy

  • The best is yet to come (4th qtr).

    Sentiment: Strong Buy

  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
    This study is currently recruiting participants. (see Contacts and Locations)
    Verified August 2014 by Roswell Park Cancer Institute
    Sponsor:
    Roswell Park Cancer Institute
    Collaborator:
    National Cancer Institute (NCI)
    Information provided by (Responsible Party):
    Roswell Park Cancer Institute

    Sentiment: Strong Buy

  • What pathogens? How big will cdx-1401 be for cldx? Thanks in advance.

    “CDX-1401 offers a novel, well-tolerated and practical approach to generating protein specific immunity that can be readily combined with other treatment strategies to boost immunity against pathogens and tumors,” said Dr. Madhav Dhodapkar, MBBS, Arthur H. and Isabel Bunker Professor of Medicine and Immunobiology, Chief of the Section of Hematology at the Department of Internal Medicine and Clinical Research Program Leader of the Hematology Program at Yale Cancer Center and lead author of the paper. “The preliminary findings in patients who received therapy with a checkpoint inhibitor following the vaccine provide further rationale for combination immunotherapy strategies, meriting further investigation.”

    Thomas Davis, MD, Senior Vice President and Chief Medical Officer of Celldex Therapeutics added, “CDX-1401 has overcome a significant historical challenge in the development of protein based vaccines by successfully targeting dendritic cells in vivo. It now sits at the forefront of a new generation of off-the-shelf dendritic cell targeted vaccines that we believe hold significant promise. Based on the results observed in this Phase 1 study, we expect CDX-1401 to enter at least two combination studies this year with both our own investigational therapies and external therapies in melanoma and other indications where we believe a dendritic cell vaccine regimen could play an important role.”

  • Then people will say I should have bought at $15+!

    Sentiment: Strong Buy

  • Hello, you can expect the same or more.

    Sentiment: Strong Buy

  • Reply to

    Careers at Celldex

    by tina_astoria Jun 17, 2014 1:55 PM
    weightbayou weightbayou Jun 17, 2014 5:28 PM Flag

    We are heading much higher.

    Sentiment: Strong Buy

  • Astrocytoma Options
    Understand the options available with an Astrocytoma diagnosis.Immunotherapy

    In some ways, therapies which stimulate a cancer-fighting immune response are the ideal way to treat the disease. Non-invasive, selective, without toxicity to healthy cells, a properly trained immune system can act as an elite search-and-destroy team.
    The bodies of each one of us contains cells in various degrees of pre-malignancy. It is mainly the proper functioning of the immune system which detects these rogue cells and destroys them before they can multiply into an active tumour. The immune system is a complex team composed of many different cell types with various, even opposite, functions. Additionally, immune cells may have differing functions depending on the cytokines and other chemical signals existing in the cellular microenvironment. Due to this plasticity of function, cancer cells have the ability to reprogram, or re-educate tumour infiltrating immune cells such as macrophages, changing their activity from cancer-fighting to cancer-promoting. This is certainly true for brain tumours, particularly high-grade tumours such as glioblastomas.
    Natural killer cells have the ability to detect and destroy malignant cells in some types of cancer. There is a common misconception that these cells are also important in the immune response against brain tumours. However, most evidence shows that natural killer cells have a very limited penetration of the blood-brain barrier, and are either rare or absent within the majority of brain tumours. Similarly, one study shows that the presence of T helper and cytotoxic T cells (which can also be trained to destroy cancer cells) is greatly increased in glioblastomas relative to lower grade tumours, and that this increase in T cell infiltration is related to blood-brain barrier leakiness, which occurs with rapid angiogenesis in glioblastoma (1).

    Sentiment: Strong Buy

  • Reply to

    Let strong buying commence on Monday!

    by weightbayou Jun 28, 2014 5:58 PM
    weightbayou weightbayou Jun 28, 2014 6:12 PM Flag

    It was probably around then. cdx-1127 will be big.

    T cells are typically stimulated to divide and mediate anti-tumor effects through a 2 signal mechanism that involves the T cell receptor stimulation (when engaged with an antigen presenting cell) and a co-stimulatory signal. CD27 can provide a potent co-stimulatory signal when engaged by its ligand CD70. However, CD70 is generally not available (to prevent unwanted stimulation of T cells). CDX-1127 can substitute for CD70 and will cause activation of T cells that are in the appropriate setting (receiving T cell receptor stimulation). This can result in a weak immune response becoming a strong response that can last for a long time.

    Some tumors (B or T cell derived malignancies) have high CD27 expression. CDX-1127 can bind these tumor cells directly and activate immune cell killing through a mechanism known as Antibody Dependent Cellular Cytotoxicity (ADCC). CDX-1127 binding to the tumor cells may also interfere with tumor cell growth by additional mechanisms.

    Sentiment: Strong Buy

  • I like the prospects for 014.
    "We believe CDX-014 will be another exciting addition to our clinical pipeline," said Tibor Keler, PhD, Senior Vice President and Chief Scientific Officer of Celldex. "The data presented today confirm that CDX-014 effectively targets the tumor marker TIM-1 in vitro and elicits significant anti-tumor activity in key models. We are currently completing manufacturing and IND-enabling studies and anticipate that CDX-014 will enter Phase 1 clinical studies in renal cell carcinoma and potentially other TIM-1 expressing tumors in 2015."

    Sentiment: Strong Buy

CRIS
1.58-0.03(-1.86%)Sep 15 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
21Vianet Group, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT